Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (NYSE American: PTHS) secured a senior secured term loan facility with Horizon Technology Finance providing $30 million funded at closing and up to $20 million more (total facility up to $50 million) to support commercialization of ZELSUVMI (berdazimer) 10.3% gel, the launches of Xepi and Xeglyze, and working capital.
The loan rate is Prime + 3.75% (10.50% currently), thirty-six month amortization start (may begin month 48 if milestones met), 60-month term, and interest-only until amortization. Pelthos issued warrants for 65,488 shares at an exercise price of $27.49. Cash as of Sept 30, 2025 was $14.2 million, and the company issued $18.0 million of convertible notes on Nov 6, 2025.
Pelthos Therapeutics (NYSE American: PTHS) acquired Xeglyze (abametapir) from Hatchtech for $1.8 million on Jan 5, 2026.
Xeglyze is an FDA-approved prescription topical treatment for head lice in patients 6 months and older (approved July 2020). Pelthos obtained worldwide commercialization rights with no future milestone, royalty, or other payments owed to Hatchtech. The company plans to relaunch Xeglyze in the first half of 2027. The release cites an estimated 6–12 million annual U.S. head-lice infestations among children ages 3–11 as the addressable market context.
Pelthos Therapeutics (NYSE American: PTHS) appointed Andrew J. Einhorn to its Board of Directors effective December 23, 2025. Einhorn will serve until the 2026 annual meeting or until his successor is qualified and joins the Audit Committee and Compensation Committee immediately.
He brings over four decades of capital markets, investment banking and C-level finance experience at clinical and commercial-stage life science companies, and currently consults at Danforth Advisors and advises Israel Biotech Fund.
Pelthos Therapeutics (NYSE American: PTHS) signed its first commercial agreement to expand patient access to ZELSUVMI™ (berdazimer) topical gel, 10.3%, an FDA‑approved at‑home treatment for molluscum contagiosum. The company entered a deal via a Group Purchasing Organization with a pharmacy benefit manager that covers more than 20 million lives; formulary inclusion updates began on December 1, 2025. ZELSUVMI launched in July 2025, is approved for patients aged one year and older, and received a Novel Drug designation from FDA in January 2024. Pelthos says the PBM partnership aims to improve coverage, distribution, and patient access to the once‑daily topical gel.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 9:30 a.m. ET at The Lotte New York Palace, 455 Madison Avenue, New York.
Institutional investors can request in-person one-on-one meetings via their Piper Sandler representative. A live webcast of the fireside chat will be available on the company’s Investors News & Events page and posted at the event webcast link approximately two hours after the presentation.
Pelthos Therapeutics (NYSE American: PTHS) reported third quarter fiscal 2025 results on November 13, 2025, following its merger and equity raise. Key commercial and corporate actions include a July 2025 launch of ZELSUVMI (first FDA-approved at‑home molluscum contagiosum treatment) that generated $7.1 million in net revenues with 2,716 units dispensed by 1,169 prescribers in Q3. The company closed a $50.1 million private placement, completed the XEPI acquisition in November 2025, and closed an $18 million convertible notes financing. Cash as of September 30, 2025 was $14.2 million.
Pelthos Therapeutics (NYSE: PTHS) acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1% and closed an $18 million private convertible notes financing on Nov 7, 2025. Pelthos paid $3.0M to Biofrontera and $1.2M to Ferrer upfront, with additional sales‑based milestones and royalties payable. Xepi is FDA‑approved for impetigo in patients two months and older; Pelthos plans a re‑launch in late 2026. The Notes bear 8.5% interest, mature Nov 6, 2027, and convert at an initial price of $34.442. Proceeds will fund the Xepi relaunch, commercial acceleration of ZELSUVMI, and working capital.
Pelthos Therapeutics (NYSE American: PTHS) will report third quarter 2025 financial results and host a conference call on Thursday, November 13, 2025 at 8:00 a.m. Eastern Time.
The company said a press release with financial results will be issued prior to the call. Management will discuss results for the quarter ended September 30, 2025, followed by a Q&A session. Dial-in details: toll-free 1-877-451-6152, international 1-201-389-0879, Conference ID 13756828. A live webcast will be available at the provided webcast URL.
Pelthos Therapeutics (NYSE: PTHS) on Oct 9, 2025 launched the Moms Against Molluscum movement and MomsAgainstMolluscum.com to unite families affected by molluscum contagiosum and share resources.
The company highlights its prescription topical ZELSUVMI (berdazimer) 10.3% gel, launched in July 2025 and described as a once-daily, at-home nitric oxide-releasing treatment. ZELSUVMI received a Novel Drug designation from the FDA in Jan 2024. The release cites disease burden: an estimated 16.7 million Americans affected and up to 6 million new U.S. incidents annually, mostly children.
Pelthos Therapeutics (NYSE American: PTHS) announced its participation in two upcoming investor conferences in September 2025. The company's CEO Scott Plesha and CFO Frank Knuettel II will represent Pelthos at the H.C. Wainwright 27th Annual Global Investment Conference in New York City and the Investor Summit Group Q3 Virtual Conference.
At the H.C. Wainwright conference, scheduled for September 8-10, 2025, management will deliver a presentation on September 10 at 10:30 A.M. ET and will be available for one-on-one meetings. The virtual Investor Summit Group conference will take place on September 16-17, 2025. A webcast of the H.C. Wainwright presentation will be available on Pelthos' website with a 90-day replay period.
FAQ
What is the current stock price of Pelthos Therapeutics (PTHS)?
What is the market cap of Pelthos Therapeutics (PTHS)?
